Please login to the form below

Not currently logged in
Email:
Password:

Actilyse

This page shows the latest Actilyse news and features for those working in and with pharma, biotech and healthcare.

Daiichi Sankyo licenses clot-busting antibody

Daiichi Sankyo licenses clot-busting antibody

as Genentech/Boehringer Ingelheim's Activase/Actilyse (alteplase), but Translational Sciences believes there is significant room for improvement.

Latest news

  • NICE stroke guidance boost for Boehringer's Actilyse NICE stroke guidance boost for Boehringer's Actilyse

    NICE stroke guidance boost for Boehringer's Actilyse. Institute changes guidance on alteplase use. ... More people suffering a stroke in the UK should get treatment with Boehringer Ingelheim's thrombolytic drug Actilyse in the wake of new NICE

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics